Pharmalot By Ed Silverman Pharmalittle: Senate committee ‘reinvites’ big drug makers to testify; can pharma use AI to solidify patents?
First Opinion By Richard Markus Biosimilars and interchangeability: The FDA’s science-based standards will ensure safety
Pharmalot By Ed Silverman Pharmalittle: Glaxo looks for a new chairman; FDA ponders whom to furlough as shutdown drags on
Pharmalot By Ed Silverman Pharmalittle: A new year brings rising drug prices; Democratic presidential contenders target drug prices
Pharmalot By Ed Silverman Pharmalittle: Drug makers to raise prices in January; Novartis names a new oncology chief, again
Pharmalot By Ed Silverman Pharmalittle: Glaxo and Pfizer will combine OTC businesses; Allergan recalls breast implants in Europe
Pharmalot By Ed Silverman Pharmalittle: Novartis eyes reinsurance for pricey gene therapies; J&J hits back over talc report
First Opinion By Michelle Hoffmann Biosimilars: the cure for sky-high drug prices or a stake in the heart of innovation?
